Sign Up to like & get recommendations! 1
Published in 2019 at "Clinical Cardiology"
DOI: 10.1002/clc.23151
Abstract: Pulmonary vascular resistance (PVR) and PVR index (PVRI) are key variables in a broad range of contexts, including prediction of outcomes in heart and liver transplantation, determining candidacy for closure of atrial or ventricular septal… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Comprehensive Physiology"
DOI: 10.1002/cphy.c210017
Abstract: The right ventricle (RV) and pulmonary arterial (PA) tree are inextricably linked, continually transferring energy back and forth in a process known as RV-PA coupling. Healthy organisms maintain this relationship in optimal balance by modulating… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13183
Abstract: This study aimed to evaluate a novel echocardiographic algorithm for quantitative estimation of pulmonary artery wedge pressure (PAWP) and pulmonary vascular resistance (PVR) in patients with heart failure and pulmonary hypertension (PH) scheduled to right… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.1415
Abstract: The Fontan procedure is considered the treatment of choice for patients with a univentricular heart defect for whom biventricular repair is not possible. The Fontan procedure entails the surgical rerouting of the systemic venous return… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "European journal of heart failure"
DOI: 10.1002/ejhf.2805
Abstract: AIMS Elevated left atrial (LA) pressure is a pathophysiologic hallmark of heart failure with preserved ejection fraction (HFpEF). Chronically elevated LA pressure leads to LA enlargement, which may impair LA function and increase pulmonary pressures.… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2834
Abstract: Interatrial shunt (IAS) devices are emerging as a novel treatment option for patients with heart failure (HF) and mildly reduced or preserved ejection fraction (HFpEF).1–3 Latent pulmonary vascular disease might affect the benefits of IAS… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "IUBMB Life"
DOI: 10.1002/iub.2588
Abstract: Metformin has potential anti‐inflammatory properties and accelerates wound healing by enhancing vascular development. In this study, we aimed to investigate the effects of metformin on pulmonary vascular development and the underlying mechanism. Newborn mice were… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12096
Abstract: Abstract Pulmonary hypertension secondary to heart failure (HF‐PH) combined with pulmonary vascular remodeling has a high mortality rate. Apolipoprotein A1 (ApoA1) has been shown to adversely affect outcomes in patients with HF. A prospective follow‐up… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12123
Abstract: Abstract The Pulmonary Vascular Research Institute GoDeep meta‐registry is a collaboration of pulmonary hypertension (PH) reference centers across the globe. Merging worldwide PH data in a central meta‐registry to allow advanced analysis of the heterogeneity… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12181
Abstract: Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is believed to involve both vascular obstruction and vasoconstriction; hence, pulmonary vasodilators such as riociguat may be beneficial. Acute vasoreactivity testing (AVT) is seldom performed routinely in CTEPH patients,… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Advances in experimental medicine and biology"
DOI: 10.1007/978-3-319-63245-2_3
Abstract: Pulmonary hypertension (PH) is a lung vascular disease with marked increases in pulmonary vascular resistance and pulmonary artery pressure (>25 mmHg at rest). In PH patients, increases in pulmonary vascular resistance lead to impaired cardiac output… read more here.